ENGN — enGene Holdings Income Statement
0.000.00%
- $416.49m
- $174.41m
- 41
- 28
- 66
- 41
Annual income statement for enGene Holdings, fiscal year end - October 31st, USD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 12.3 | 14.1 | 19.4 | 29.2 |
Operating Profit | -12.3 | -14.1 | -19.4 | -29.2 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -15.1 | -23.4 | -24.4 | -99.9 |
Provision for Income Taxes | ||||
Net Income After Taxes | -15.1 | -23.4 | -24.5 | -99.9 |
Net Income Before Extraordinary Items | ||||
Net Income | -15.1 | -23.4 | -24.5 | -99.9 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -16.6 | -22.3 | -29 | -105 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.785 | -1.03 | -1.25 | -4.43 |